What is Peptide Retatrutide? Mechanism, Clinical Results, and How the Triple-Agonist Works
The landscape of metabolic science and weight-loss pharmacotherapy is evolving rapidly. Following the breakthroughs of single-agonist GLP-1 medications like semaglutide (Ozempic®, Wegovy®) and dual-agonist GLP-1/GIP medications like tirzepatide (Mounjaro®, Zepbound®), a next-generation molecule has emerged: the peptide retatrutide.
Developed by Eli Lilly and Company (code name LY3437943), the peptide retatrutide represents a new frontier in obesity and metabolic disease treatment. Commonly referred to as a “triple agonist” or “tri-agonist,” this experimental compound simultaneously targets three distinct metabolic hormone pathways.
Here is a comprehensive breakdown of what the peptide retatrutide is, how its unique triple-action mechanism works, its pivotal Phase 3 clinical trial results, and how it compares to existing weight-loss medications.
How Does the Peptide Retatrutide Work? The Triple-Agonist Mechanism
Unlike first-generation treatments that activate a single hormone receptor or second-generation drugs that activate two, the peptide retatrutide simultaneously binds to and activates three natural gut and metabolic hormone receptors:
Peptide Retatrutide Phase 3 Clinical Trial Results
In global Phase 3 clinical trials—including the pivotal TRIUMPH and TRANSCEND trial programs—the peptide retatrutide has demonstrated significant efficacy in body weight reduction and glycemic control.
Efficacy & Weight Loss Data
Non-Diabetic Obesity (TRIUMPH-1): In Phase 3 trial readouts, adults taking the highest 12 mg weekly dose achieved a mean body weight loss of 28.3% at 80 weeks (an average of over 70 lbs lost). In a 104-week extension group, mean weight loss reached 30.3%.
Obesity with Knee Osteoarthritis (TRIUMPH-4): Trial data showed that adults taking the 12 mg dose achieved an average weight loss of 28.7% at 68 weeks along with a 75% reduction in knee osteoarthritis pain.
Obesity with Type 2 Diabetes (TRIUMPH-2): Adults with type 2 diabetes achieved an average body weight reduction of 20.8% (up to 49.6 lbs) at 80 weeks, accompanied by significant HbA1c reductions.
Severe Obesity with Cardiovascular Risk (TRIUMPH-3): Participants lost an average of 22.6% of their body weight, with substantial drops in triglycerides (-37%) and inflammatory markers like hsCRP (-51%).
Developed by Eli Lilly and Company (code name LY3437943), the peptide retatrutide represents a new frontier in obesity and metabolic disease treatment. Commonly referred to as a “triple agonist” or “tri-agonist,” this experimental compound simultaneously targets three distinct metabolic hormone pathways.
Here is a comprehensive breakdown of what the peptide retatrutide is, how its unique triple-action mechanism works, its pivotal Phase 3 clinical trial results, and how it compares to existing weight-loss medications.
Liver Fat & MASH Resolution
Sub-studies assessing metabolic liver health revealed that the peptide retatrutide produced up to an 82% to 90% reduction in liver fat, with a majority of participants clearing excess liver fat completely due to targeted hepatic glucagon receptor activity.